-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
October is the centralized disclosure period for the third quarterly reports, and statistics are not complete.
Up to now, more than 80 companies in the pharmaceutical industry have released their third quarterly reports (announcements), of which the valuation is less than 30 times (greater than 0) and the third quarterly reports (including the median).
There are 14 pharmaceutical and biological stocks with net profit growth of more than 30% year-on-year, including Botuo Bio, Lanfan Medical, Daan Gene, Kelun Pharmaceutical, etc.
, of which Lanfan Medical, Kehua Bio, Mingde Bio, etc.
have low valuations At 10 times
.
On the whole, the relative valuation of the pharmaceutical sector is becoming more reasonable
.
So, can the pharmaceutical sector still be deployed? Soochow Securities released a research report stating that from the mid-term perspective, the growth determined by the pharmaceutical sector will still be one of the main directions for market-wide investment in 2022.
October and even Q4 will be the best time to deploy the pharmaceutical sector, and continue to focus on optimism.
CXO, research services, innovative drugs, specialty medical equipment and medical services
.
In addition, the broker believes that in the short term, the focus is on stock selection in the three quarterly reports.
The quarterly report exceeding expectations is likely to be the main theme of the pharmaceutical sector in October.
The Q3 quarterly report exceeds the expected number of listed companies or will far exceed the interim report, CXO and specialty APIs, etc.
It may be more obvious
.
In fact, the CXO sector is generally optimistic in the industry.
In the first half of this year, most of the stock prices in this sector performed relatively well
.
Among them, Bo Teng shares and Zhaoyan New Drug are close to 100%, and Yaoshi Technology and Kanglong Chemical have also increased by more than 50%
.
At the same time, the overall performance of CXO listed companies also maintained high growth, with profit growth slightly higher than revenue growth
.
The data shows that in the first half of 2021, the total revenue growth rate of 10 CXO companies was 45.
6%, and the total net profit growth rate of the parent company was 49.
7%.
The overall growth rate was maintained at a high speed, and the profit growth rate was slightly faster than the revenue growth rate, which is enough to see The profitability of the industry is improving
.
Southwest Securities recently forecasted the performance of listed companies in the CXO field for the third quarter of 2021.
It indicated that the CXO sector continued its high boom and maintained high performance growth.
Among them, Medicilon (+149%~185%) achieved substantial growth.
Zhou Pharmaceutical (+60%~90% year-on-year), Proton (+45%~50% year-on-year), Kailaiying (+40%~45% year-on-year), Yakushi Technology (+40%~45% year-on-year) , WuXi AppTec's 2021Q3 revenue will increase by 35%-45% year-on-year
.
Shanxi Securities also issued a report a few days ago that the pharmaceutical and biological market has continued to pick up recently, and CXO and other high-prosperity areas have performed well.
The current overall valuation of the sector is in a reasonable range.
It is recommended to actively seize the allocation opportunities
.
The brokerage firm is optimistic about subdivisions such as innovative drugs, medical outsourcing services, and self-consumption
.
Among them, in the medical outsourcing service (CDMO/CMO/CRO) sector, it believes that the domestic CXO industry is developing rapidly due to the development of innovative drugs and other factors.
With the advancement of industry policies and the improvement of drug quality standards, industry concentration is expected to increase.
Once improved, it is recommended to pay attention to industry leaders and market segments, such as WuXi AppTec and Kanglong Chemical
.
At the same time, the three quarterly reports are about to usher in a concentrated disclosure period, and it is recommended to pay attention to the targets of the rapid growth of CXO industry performance
.
In addition, the specialty API sector is also favored by many brokerages, including Guohai Securities and Zhongtai Securities
.
Among them, Guohai Securities stated that China's API industry has the dual growth potential of upgrading itself and undertaking the transfer of the global industrial chain, and 2020 is the period for a new round of intensive production capacity construction in the API industry.
This year is expected to begin to concentrate on contributing profits, so it is optimistic.
2021 Davis Double-click the API industry usher, proposes a focus on new drug substance manufacturing upgrades related subject (CDMO) logic, such as Provincetown medicine, Jiuzhou Pharmaceutical, Sky shares, the United States and Novartis, medicine and other Aoxiang
.
Up to now, more than 80 companies in the pharmaceutical industry have released their third quarterly reports (announcements), of which the valuation is less than 30 times (greater than 0) and the third quarterly reports (including the median).
There are 14 pharmaceutical and biological stocks with net profit growth of more than 30% year-on-year, including Botuo Bio, Lanfan Medical, Daan Gene, Kelun Pharmaceutical, etc.
, of which Lanfan Medical, Kehua Bio, Mingde Bio, etc.
have low valuations At 10 times
.
On the whole, the relative valuation of the pharmaceutical sector is becoming more reasonable
.
So, can the pharmaceutical sector still be deployed? Soochow Securities released a research report stating that from the mid-term perspective, the growth determined by the pharmaceutical sector will still be one of the main directions for market-wide investment in 2022.
October and even Q4 will be the best time to deploy the pharmaceutical sector, and continue to focus on optimism.
CXO, research services, innovative drugs, specialty medical equipment and medical services
.
In addition, the broker believes that in the short term, the focus is on stock selection in the three quarterly reports.
The quarterly report exceeding expectations is likely to be the main theme of the pharmaceutical sector in October.
The Q3 quarterly report exceeds the expected number of listed companies or will far exceed the interim report, CXO and specialty APIs, etc.
It may be more obvious
.
In fact, the CXO sector is generally optimistic in the industry.
In the first half of this year, most of the stock prices in this sector performed relatively well
.
Among them, Bo Teng shares and Zhaoyan New Drug are close to 100%, and Yaoshi Technology and Kanglong Chemical have also increased by more than 50%
.
At the same time, the overall performance of CXO listed companies also maintained high growth, with profit growth slightly higher than revenue growth
.
The data shows that in the first half of 2021, the total revenue growth rate of 10 CXO companies was 45.
6%, and the total net profit growth rate of the parent company was 49.
7%.
The overall growth rate was maintained at a high speed, and the profit growth rate was slightly faster than the revenue growth rate, which is enough to see The profitability of the industry is improving
.
Southwest Securities recently forecasted the performance of listed companies in the CXO field for the third quarter of 2021.
It indicated that the CXO sector continued its high boom and maintained high performance growth.
Among them, Medicilon (+149%~185%) achieved substantial growth.
Zhou Pharmaceutical (+60%~90% year-on-year), Proton (+45%~50% year-on-year), Kailaiying (+40%~45% year-on-year), Yakushi Technology (+40%~45% year-on-year) , WuXi AppTec's 2021Q3 revenue will increase by 35%-45% year-on-year
.
Shanxi Securities also issued a report a few days ago that the pharmaceutical and biological market has continued to pick up recently, and CXO and other high-prosperity areas have performed well.
The current overall valuation of the sector is in a reasonable range.
It is recommended to actively seize the allocation opportunities
.
The brokerage firm is optimistic about subdivisions such as innovative drugs, medical outsourcing services, and self-consumption
.
Among them, in the medical outsourcing service (CDMO/CMO/CRO) sector, it believes that the domestic CXO industry is developing rapidly due to the development of innovative drugs and other factors.
With the advancement of industry policies and the improvement of drug quality standards, industry concentration is expected to increase.
Once improved, it is recommended to pay attention to industry leaders and market segments, such as WuXi AppTec and Kanglong Chemical
.
At the same time, the three quarterly reports are about to usher in a concentrated disclosure period, and it is recommended to pay attention to the targets of the rapid growth of CXO industry performance
.
In addition, the specialty API sector is also favored by many brokerages, including Guohai Securities and Zhongtai Securities
.
Among them, Guohai Securities stated that China's API industry has the dual growth potential of upgrading itself and undertaking the transfer of the global industrial chain, and 2020 is the period for a new round of intensive production capacity construction in the API industry.
This year is expected to begin to concentrate on contributing profits, so it is optimistic.
2021 Davis Double-click the API industry usher, proposes a focus on new drug substance manufacturing upgrades related subject (CDMO) logic, such as Provincetown medicine, Jiuzhou Pharmaceutical, Sky shares, the United States and Novartis, medicine and other Aoxiang
.
